Michael A. Mussallem - Feb 14, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Chairman & CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Feb 14, 2023
Transactions value $
-$496,405
Form type
4
Date filed
2/14/2023, 06:14 PM
Previous filing
Jan 13, 2023
Next filing
Mar 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1.03M +29.4K +18.67% $35.20 187K Feb 14, 2023 Direct F1
transaction EW Common Stock Sale -$280K -3.6K -1.93% $77.75 183K Feb 14, 2023 Direct F1, F2
transaction EW Common Stock Gift $0 -9.5K -5.19% $0.00 174K Feb 14, 2023 Direct
transaction EW Common Stock Sale -$1.25M -16.3K -9.37% $76.83 157K Feb 14, 2023 Direct F1, F3
transaction EW Common Stock Gift $0 +9.5K +0.27% $0.00 3.49M Feb 14, 2023 By Living Trust
holding EW Common Stock 372K Feb 14, 2023 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -29.4K -25% $0.00 88.1K Feb 14, 2023 Common Stock 29.4K $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $77.285 to $78.110 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $76.280 to $77.280 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.